The Wall Street Transcript
The Wall Street Transcript - In-Depth Interviews for Investors

Investing Strategies

April 09, 2015

Buy ($175)

Topics covered: Small-Cap Investing, Reasonable Valuations, Equity and High Yield Mix, Downside Risk Focus, Disciplined and Quantitative Investing, Christian-Based Investing, Bond

Companies covered: Littelfuse, Inc. (NASDAQ:LFUS), Dresser-Rand Group Inc. (NYSE:DRC), NetApp, Inc. (NASDAQ:NTAP), NewMarket Corporation (NYSE:NEU), Family Dollar Stores, Inc. (NYSE:FDO), Dollar Tree, Inc. (NASDAQ:DLTR), Atwood Oceanics, Inc. (NYSE:ATW)

Using a Focused, Disciplined and Quantitative Approach
Neil J. Hennessy
Owning Good Businesses at Reasonable Valuations in the Small-Cap Space
Michael L. Johnson;  Mark Wynegar
Building a Portfolio with a Mix of Bonds, Equities and High Yield
Ramin Arani
Investing Based on Christian Values
Ron C. Dugan;  John R. Jones
Investing with a Focus on Downside Risk
Stephen M. Goddard
Top Company Interviews

Microsoft Corporation
Intel Corporation
Pfizer, Inc.
General Electric Company
Walmart Inc.
International Business Machines Corporation
Citigroup Inc.
Exxon Mobil Corporation
Bank of America Corporation
Dell Inc.
Verizon Communications Inc.
Alphabet Inc

Register for a Free Account to gain greater access to The Wall Street Transcript right now

CEO INTERVIEWS
Interview with the CEO: BetterLife Pharma Inc. (OTCMKTS:BETRF)
Interview with the CEO: Cansortium Inc. (OTCMKTS:CNTMF)
Interview with the Co-CEO and the CAO: Planet 13 Holdings Inc. (OTCMKTS:PLNH)
SECTOR ROUNDTABLES
Natural Gas Weighs Heavy On E&P Near-Term Prospects
Roundtable Forum:optimism Despite Uncertainty In For-profit Education
Roundtable Forum:a Shift In Focus To Natural Gas From Oil
MONEY MANAGER INTERVIEWS
Profitability Strategy Pays Off for Bank IT Company Q2 Holdings
Three Mid-Cap Names Using Their Balance Sheets to Create Value
Look Beyond Traditional Emerging Markets for More Diversification, Less Risk
ANALYST INTERVIEWS
Five Companies Dominate in Psychedelics-Based Drug Development
Cidara’s Long-Acting Antiviral Drug Could Be a Game Changer
Spotting Potential in the High-Risk, High Reward Neuroscience Space
Since 1963
© The Wall Street Transcript 2016, 2024
Terms and Conditions
Privacy Policy